Background: Evidence suggests that cytokines (IL-6) and alteration of the hypothalamic-pituitary-adrenal (HPA) axis play a crucial role in the etiology of depression. Patients with cancer show elevated prevalence rates for depression. The objective of this cross-sectional study was to investigate the associations between these abnormalities and depression. Methods: Plasma concentrations of IL-6 and cortisol were measured in cancer patients with (N = 31) and without depression (N = 83). The relative diurnal variation of cortisol (cortisol VAR), expressed in percentage, was calculated. Results: There was a significant difference in median plasma concentration of IL-6 between the patients with depression and those without (18.7 vs 2.7 pg/mL; P < .001). Relative cortisol VAR was decreased in depressed patients as compared with patients without depression (11.72% vs 60.6%, P = .037). A positive correlation between the depressive symptoms and IL-6 concentration was found (r = 0.469, P < .001). Negative correlations were found between cortisol VAR versus depressive symptoms and cortisol VAR versus IL-6 (r = -0.6, P < .001 and r = -0.52, P < .001, respectively). IL-6 (odds ratio [OR] = 1.1; 95% confidence interval [CI] = 1.0-1.2; P = .006) and cortisol VAR (OR = 1.3; 95%CI = 1.0-1.4; P = .02) are independently associated with depression. Conclusions: Depression in cancer is associated with increased plasma IL-6 concentrations and dysfunction of the HPA axis.
Introduction
Depression in patients with cancer occurs at a high rate, with a median prevalence of 22% to 29% and is comparable with that seen in hospitalized patients with other serious medical conditions. 1, 2 It has therefore been suggested that cancer should be viewed as a significant risk factor for developing depression rather than depression being its inevitable consequence. 3 Numerous studies of immunological and neuroendocrine abnormalities in noncancer patients with depression have been published to date. Among these are elevated levels of cortisol in the plasma and a reduced diurnal variability in cortisol levels, 4 suggesting a disturbed circadian function of the hypothalamic-pituitary-adrenal (HPA)-axis, 5, 6 possibly because of an impaired glucocorticoid receptor. 7 The concept of sickness behavior, a syndrome induced by inflammation, sharing many characteristics with depression, 8 has lead to the speculation that the pro-inflammatory cytokine interleukin-6 (IL-6) might also play a role in depression. 9 IL-6 is produced not only by a variety of immune cells during inflammation but also by nonimmune cells such as endothelial cells, endocrinal cells, and tumor cells. 10, 11 Its production can be stimulated by catecholamines and suppressed by glucocorticoids. 12, 13 Furthermore, IL-6 is a potent activator of the HPA axis, characterized by an increased production of cortisol and depressive mood. 14, 15 We previously published a study examining the specificity and sensitivity of IL-6 and the HPA axis dysfunction as biomarkers of depression in cancer patients. 16 In this followup analysis of the same cohort, we would like to examine the relationships between depression, levels of IL-6, and disturbance of circadian function of the HPA axis in a larger group of hospitalized patients with metastatic cancer and integrate this into a conceptual framework.
Methods Patients
All patients were assessed in the Department of Oncology at the University Hospital Charité Mitte in Berlin, Germany. The study had been approved by our institutional review board. A total of 114 inpatients with advanced metastatic cancer (stage IV) were screened for depression and gave their written informed consent. All patients were receiving chemotherapy during their stay in the oncology ward. Patient characteristics such as age, gender, cancer type, and Karnofsky performance status, 17 were recorded. All patients presented themselves with a Mini-Mental State Examination (MMSE) score of at least 24. Exclusion criteria were untreated endocrine diseases, renal insufficiency requiring dialysis or any form of neurological malfunction, that is, leptomeningeal carcinomatosis, known brain metastasis, or a previous history of affective disorder. None of the patients were receiving antidepressant drugs, anticonvulsants, or other psychotrophic medication for treatment of affective disorders. Other exclusion criteria were current evidence of substance/alcohol abuse, long-term steroid use (>8 weeks), and any use of steroids within the last 8 weeks, which could interfere with HPA axis function.
Procedure
To measure the level of depressive symptoms, all participants completed the Hospital Anxiety and Depression Scale-Depression (HADS-D), a self-rated and well-validated 14-item scale 18 developed specially for assessing depressive symptoms in medically ill patients. 19 A threshold score of >11 on the depression scale (0-21) is considered to indicate a probable diagnosis of clinical depression in patients with somatic disease. 20 The diagnosis of major depression was established by using the depression section of the Structured Clinical Interview for DSM-IV (Diagnostic and Sta tistical Manual of Mental Disorders, 4th edition) Axis I Disorders (SCID). 21, 22 After being woken up at 7:00 am by the nursing staff, blood samples for measurement of IL-6 and cortisol (8:00 am) were collected at 8:00 am from the patients. At 8:00 pm, another blood collection for the evening cortisol (8:00 pm) concentration was performed. Plasma IL-6 concentrations were measured with commercially available kits following the manufacturer's protocol (Immulite /Immulite 1000 IL-6, DPC Biermann, Bad Neuheim, Germany). Samples were assayed in duplicate, and IL-6 concentrations were derived from standard curve composed of serial dilutions (2 to 625 pg/mL) of recombinant human IL-6. Assay sensitivity was <2 pg/mL. The mean interassay and intra-assay coefficients of variation were 10.9% and 3.6%, respectively. Plasma concentrations of cortisol were measured by using radioimmunoassay (GammaCoat, Incstar, Stillware, MN). The mean interassay and intra-assay coefficients of variation were 8.8% and 6.6%, respectively. All samples were assayed by personnel who were blind to the diagnostic identity of the study subjects.
Statistical Analysis
Distribution and variance of the data was analyzed with the Lilliefors test. Results with normal distribution, such as age, Karnofsky index, and HADS-D score were presented as means and standard deviation. The t test was used to compare these variables between the 2 groups. Because of the skewed distribution of IL-6, cortisol plasma concentrations at 8:00 am and 8:00 pm, and relative diurnal variation of cortisol (cortisol VAR), the medians and range were calculated.
Cortisol VAR, expressed in percentage, was calculated as the change in cortisol (Dcortisol = cortisol 8:00 am minus cortisol 8:00 pm) divided by cortisol 8:00 am and multiplied by 100. The Mann-Whitney U test was used to compare these variables between the groups. All results were considered significant at P < .05 (2-tailed). Spearman rank order correlations (rho) were used to determine the relationship between HADS-D scores, plasma IL-6, and cortisol VAR. In addition, a multiple logistic regression analysis was performed to evaluate whether IL-6 levels and cortisol VAR were independently associated with depression.
Results
Of the 114 patients screened, 31 (27%) patients presented themselves with depression, and 83 (73%) patients showed no significant depressive symptoms.
Evaluations of demographic and clinical characteristics of the 114 patients with advanced metastatic disease evaluated are shown in Table 1 . All patients were Caucasian. The 2 groups did not differ in mean age or Karnofsky index (62.7 vs 59.4 years and 62.1% vs 65.2%, respectively). There was a significant difference in median plasma concentration of IL-6 between patients with depression (18.7 pg/mL) and patients without depression (2.7 pg/mL). Furthermore, cancer patients with depression exhibited signi ficantly higher plasma cortisol concentrations at 8:00 am (506.5 vs 387.5 nmol/L) and 8:00 pm (445.5 vs 130.5 nmol/L; Figure 1 ). DCortisol was smaller in depression (75.5 vs 211.5), indicating flattened amplitude between high morning plasma cortisol concentrations and low evening concentrations. The relative cortisol VAR (11.72% vs 60.6%, respectively) was significantly decreased in the cancer patients with depression compared with the cortisol VAR in the cancer patients without depression (Figure 2) . The relationship between the level of depression as measured by the HADS-D score, concentrations of IL-6 in the plasma, and cortisol VAR was also evaluated. A positive correlation between the HADS-D score and the plasma IL-6 concentrations was found (r = 0.6, P < .001; Figure 3 ). There was a significant negative correlation between the HADS-D score and cortisol VAR (r = -0.6, P < .001; Figure 4 ) and between IL-6 and cortisol VAR (r = -0.52, P < .001). In addition, the multiple logistic regression analysis with depression as the dependent variable and IL-6 and cortisol VAR as the independent variables, showed that IL-6 (odds ratio [OR] = 1.1; 95% confidence interval [CI] = 1.0-1.2; P = .006) and cortisol VAR (OR = 1.3; 95% CI = 1.0-1.4; P = .02) were independently associated with depression.
Discussion
Several studies have tried to link cytokines, especially IL-6, to depression in patients with and without cancer. 23, 24 This study demonstrates a linear relationship between IL-6 plasma concentrations and level of depressive mood. Patients whose level of depressive symptoms fulfilled the criteria for the diagnosis of major depression showed elevated plasma concentrations of IL-6 compared with patients without this diagnosis.
Furthermore, the increase in IL-6 concentration was significantly correlated with a disturbance of the circadian function of the HPA axis, as seen by the flattened amplitude of cortisol levels. To our knowledge, such a correlation has not been established so far in cancer patients.
The mechanism by which IL-6 can activate the HPA axis is still not fully understood, but pro-inflammatory cytokines show the ability to induce a state of impaired glucocorticoidmediated feedback inhibition of the HPA axis, 25 thus inducing a state of HPA hyperactivation.
Patients with major depression exhibited a significant reduction in the relative diurnal variance of cortisol, as a measure of HPA axis perturbation, compared with the patients without depression. Evidence for a dysregulation of the HPA function in depressive patients without cancer has been reported extensively. 5, 7 In patients with cancer, however, this has not been shown conclusively. 15 This study tried to compile a significantly large and homogenous sample, concerning confounding factors, such as age, medication, performance status, and concomitant disease. Even though different cancer types were included, all patients had advanced metastatic (stage IV) cancer and were receiving chemotherapy as inpatients. Both patient groups had a Karnofsky performance status >60% and did not differ in age. Differences in the HPA activity therefore cannot be age related. The hospital setting insured a uniform wakening time in the morning at around 7:00 am.
There are limitations to these results. Although none of the patients was in eminent pain, a high percentage of cancer patients were under chronic pain medication. So far the role of pain in the pathophysiology of depression remains unclear. Some authors suggest that depression may represent a consequence of pain, whereas others find that depression contributes significantly to the intensity of pain. [26] [27] [28] Diagnosing depression in cancer patients is often not clear cut because symptoms inherent to cancer disease and treatment often overlap with symptoms used as diagnostic criteria for depression, established by the DSM-IV. 29 Hence, some authors have suggested using an exclusive approach by removing criteria such as anorexia and fatigue from the list of diagnostic symptoms and emphasizing anhedonia. 30 We, however, felt that excluding such symptoms increases the possibility of misdiagnosis because the origin of overlapping symptoms can rarely be identified with certainty and therefore included all DSM-IV criteria for making the diagnosis. The HADS has gotten mixed reviews in its ability to identify depression as a diagnostic tool among cancer patients. The sensitivity and specificity of the HADS range from 65% to 91% and from 66% to 96%, respectively, in cancer patients, depending on the cutoff values used and homogeneity of the sample. However, HADS has been shown to perform well in assessing symptom severity in depressed somatic patients. 31 Our findings are of correlational nature and thus limit causal inferences. However, an attempt to establish causality between depression, IL-6 concentration, and HPA function can be made on the basis of biological plausibility. Musselman et al 23 posed the question that if IL-6 were to play a direct role in inducing major depression in cancer, then other diseases associated with immune activation due to tissue destruction and associated inflammation may also be at risk for depression. Rheumatoid arthritis and coronary artery disease have shown an increase in inflammatory markers and a clear association with depression, comparable with that of cancer. [32] [33] [34] [35] Inflammation due to tissue destruction is possibly not the only source of IL-6. Increased adrenaline concentrations can induce a continued de novo synthesis of IL-6 in a time-dose dependent manner. 36, 37 Therefore, strong emotional stress, as experienced in cancer, could induce high IL-6 plasma concentrations, independent of inflammation.
Finally, the question arises why all cancer patients with increased IL-6 concentrations do not develop depression. Modell et al 38 reported a reduced HPA axis suppression by dexamethasone in first-degree relatives of patients with major depression, supporting the hypothesis that this altered feedback inhibition may represent an inherited genetic vulnerability, expressed when certain risk factors accumulate. In this regard, the possibility of an inherited genetic vulnerability and the influence of certain risk factors, that is, IL-6, on the development of depression need further investigation. Furthermore, IL-6 and the HPA axis dysfunction could be useful biomarkers in the diagnosis and treatment for depression in cancer patients.
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